カテゴリ： MarketsandMarkets, 世界, 医療/バイオ

医薬品受託製造のグローバル市場予測（～2028）：医薬品製造サービス、医薬品開発サービス、生物製剤製造サービス

■ 英語タイトル：Pharmaceutical Contract Manufacturing Market by Service (Pharmaceutical (API, FDF - Tablet, Capsule, Injectable)), Biologic (API, FDF), Drug Development), End User (Big Pharma, Small & Medium-sized Pharma, Generic Pharma) - Global Forecast to 2028

調査会社MarketsandMarkets社が発行したリサーチレポート（データ管理コード：PH7263-23）■ 発行会社/調査会社：MarketsandMarkets
■ 商品コード：PH7263-23
■ 発行日：2023年4月19日
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：279
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥752,400見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥1,010,800見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,238,800見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[医薬品受託製造のグローバル市場予測（～2028）：医薬品製造サービス、医薬品開発サービス、生物製剤製造サービス]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

MarketsandMarkets社は、世界の医薬品受託製造市場規模が2023年1,765億ドルから2028年2,583億ドルまで、予測期間中、年平均7.9%成長すると予測しています。当調査資料では、医薬品受託製造の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、サービス別（医薬品製造サービス、医薬品開発サービス、生物製剤製造サービス）分析、エンドユーザー別（大手製薬会社、中小製薬会社、ジェネリック医薬品企業、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ）分析、競争状況などの内容をまとめています。なお、当市場の主要企業には、Thermo Fisher Scientific Inc. (US)、Catalent, Inc. (US)、Lonza Group (Switzerland)、AbbVie, Inc. (US)、WuXi AppTec (China)、Evonik Industries AG (Germany)、Samsung Biologics. (South Korea)などが含まれています。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の医薬品受託製造市場規模：サービス別
　 - 医薬品製造サービスの市場規模
　 - 医薬品開発サービスの市場規模
　 - 生物製剤製造サービスの市場規模
・世界の医薬品受託製造市場規模：エンドユーザー別
　 - 大手製薬会社におけ市場規模
　 - 中小製薬会社におけ市場規模
　 - ジェネリック医薬品企業におけ市場規模
　 - その他エンドユーザーにおける市場規模
・世界の医薬品受託製造市場規模：地域別
　 - 北米の医薬品受託製造市場規模
　 - ヨーロッパの医薬品受託製造市場規模
　 - アジア太平洋の医薬品受託製造市場規模
　 - 中東/アフリカの医薬品受託製造市場規模
　 - 中南米の医薬品受託製造市場規模
・競争状況
・企業情報

“世界の医薬品開発・受託製造市場規模は、2023年の1,765億米ドルから2028年には2,583億米ドルに達し、予測期間中の年平均成長率は7.9%と予測”
低コストによるジェネリック医薬品の需要増加や、ブロックバスター医薬品の特許切れが迫っていることなどの要因が、企業を中核機能への集中に向かわせ、CDMOサービスの需要を支え、市場の成長を加速させています。

“生物学的製剤製造サービス分野は、2023年から2028年の予測期間中に最も高いCAGRで成長する可能性が高い”
医薬品開発・受託製造市場は、サービス別に医薬品製造サービス、医薬品開発サービス、生物学的製剤製造サービスに区分されます。生物学的製剤製造サービス分野は、予測期間中に最も高いCAGRで成長すると予測されています。成長の背景には、生物製剤、標的薬物療法、細胞・遺伝子治療パイプライン研究の増加に対する需要の高まりがあります。これらの要因は、セグメント別の成長にプラスの影響を与えそうです。

“大手製薬会社セグメントは、2023-2028年の予測期間中に最も高いCAGRで成長する可能性が高い”
医薬品開発・受託製造市場は、エンドユーザー別に大手製薬企業、中堅・中小製薬企業、ジェネリック製薬企業、その他のエンドユーザー（学術機関、小規模CDMO、CRO）に区分されます。2022年の医薬品開発・受託製造市場では、大手製薬企業セグメントが圧倒的なシェアを占めています。このセグメントの大きなシェアは、製薬大手が新分子の発見・開発のための研究開発を増やすなど、中核的な活動に重点を置くようになり、製造サービスのアウトソーシングを後押ししていることに起因しています。これが市場成長を予測する主な要因の1つです。

“アジア太平洋地域はより速いペースで成長”
医薬品開発・受託製造市場は、北米、欧州、アジア太平洋地域、中南米、中東・アフリカに分けられます。2022年には、北米が医薬品開発・受託製造市場で圧倒的なシェアを占めました。同地域の優位性は、同地域における大手企業の存在や、医薬品開発・受託製造の継続的な研究活動など、さまざまな要因によるものです。アジア太平洋地域は、個別化治療に対する意識の高まり、同地域におけるジェネリック医薬品に対する政府のイニシアチブの高まり、医薬品開発・受託製造市場における新たな市場プレイヤーの出現など、さまざまな要因により、より速いペースで成長する可能性があります。

本レポートのために実施した一次インタビューは以下のように分類されます：
– 回答者別 供給側60％、需要側40％
– 回答者の役職別（供給側） 管理職-45%、CXOおよび取締役-25%、経営幹部-15%、その他-15.0％
– 地域別 北米 -40%、欧州 -25%、アジア太平洋地域 -20%、中南米 -10%、中東・アフリカ -5％

レポート掲載企業リスト
• Thermo Fisher Scientific, Inc. (US)
• Catalent, Inc. (US)
• Lonza Group (Switzerland)
• AbbVie, Inc. (US)
• WuXi AppTec (China)
• Evonik Industries AG (Germany)
• Samsung Biologics. (South Korea)
• Boehringer Ingelheim International GmbH. (Germany)
• Siegfried Holding AG (Switzerland)
• Piramal Pharma Solutions (India)
• Recipharm AB. (Sweden)
• Eurofins Scientific (Luxembourg)
• FUJIFILM Holdings Corporation (Japan)
• Almac Group (UK)
• Vetter Pharma (Germany)
• Delpharm Holdings (France)
• Yuhan Corporation (South Korea)
• Curia Global, Inc. (US)
• Charles River Laboratories. (US)
• Lannett Company, Inc. (US)
• Cambrex Corporation. (US)
• FAMAR Healthcare Services (France)
• Biocon Limited (India)
• Sai Life Sciences Limited (India)
• PCI Pharma Services (US).

調査範囲
本レポートは、医薬品開発・受託製造市場の詳細な実態を明らかにします。サービス、エンドユーザー、地域など、さまざまなセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要な市場プレイヤーの会社概要、最近の動向、主要な市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点
本レポートは、医薬品開発・受託製造市場全体とそのサブセグメントについて、最も近似した収益数字を提供することで、市場リーダーや新規参入者を支援します。また、利害関係者が競争状況をより良く理解し、より多くの洞察を得ることで、自社のビジネスをより良く位置付け、適切な市場参入戦略を立てるのにも役立ちます。本レポートにより、関係者は市場動向を理解し、主要な市場促進要因、阻害要因、機会、課題に関する情報を得ることができます。

本レポートは、以下のポイントに関する洞察を提供します：
– 医薬品開発・受託製造市場の成長に影響を与える主な促進要因（精密医薬品への投資の増加、特許切れとジェネリック医薬品需要の増加、自社医薬品開発コストの高騰、CDMOによる先端製造技術への投資）、阻害要因（各地域で異なる規制要件）、機会（細胞・遺伝子治療への需要の増加、ワンストップショップモデルへの傾斜の高まり、新興国における市場拡大、核医学の成長）、課題（シリアル化の導入、知的財産リスク）分析
– サービスの開発/革新： 新たに開始されたサービスに関する詳細な洞察、医薬品開発・受託製造市場の技術評価
– 市場開発： 有利な市場に関する包括的な情報 – 当レポートでは、さまざまな地域の医薬品開発・受託製造市場を分析
– 市場の多様化： 医薬品開発・受託製造市場における新サービス、未開拓の地域、最近の開発、投資に関する詳細な情報
– 競争力の評価： Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group (Switzerland), AbbVie, Inc. (US), WuXi AppTec (China) など、医薬品開発・受託製造市場における主要企業の市場シェア、成長戦略、サービス内容を詳細に評価

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION 36
1.2.1 INCLUSIONS AND EXCLUSIONS 36
1.3 MARKET SCOPE 37
1.4 YEARS CONSIDERED 37
1.5 CURRENCY CONSIDERED 38
1.6 STAKEHOLDERS 38
1.7 LIMITATIONS 38
1.8 SUMMARY OF CHANGES 39
1.9 RECESSION IMPACT 39
2 RESEARCH METHODOLOGY 40
2.1 RESEARCH DATA 40
FIGURE 1 RESEARCH DESIGN 40
2.1.1 SECONDARY DATA 41
2.1.2 PRIMARY DATA 42
FIGURE 2 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: BREAKDOWN OF PRIMARIES 42
2.2 MARKET SIZE ESTIMATION 43
FIGURE 3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022 43
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 44
FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2022 44
2.2.1 INSIGHTS FROM PRIMARIES 46
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 46
2.2.2 SEGMENT ASSESSMENT (BY SERVICE AND END USER) 46
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 46
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 47
FIGURE 8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: CAGR PROJECTIONS, 2023–2028 47
FIGURE 9 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 48
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 49
FIGURE 10 DATA TRIANGULATION METHODOLOGY 49
2.5 RESEARCH ASSUMPTIONS 50
2.6 RISK ANALYSIS 50

2.7 IMPACT ANALYSIS OF RECESSION ON PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 50
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2027 (% GROWTH) 51
TABLE 2 US HEALTH EXPENDITURE, 2019–2027 (USD MILLION) 51
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 51
3 EXECUTIVE SUMMARY 52
FIGURE 11 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2023 VS. 2028 (USD BILLION) 52
FIGURE 12 BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2023 VS. 2028 (USD BILLION) 53
FIGURE 13 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2023 VS. 2028 (USD BILLION) 53
FIGURE 14 GEOGRAPHICAL SNAPSHOT: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 54
4 PREMIUM INSIGHTS 56
4.1 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET OVERVIEW 56
FIGURE 15 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH 56
4.2 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE & COUNTRY (2022) 57
FIGURE 16 PHARMACEUTICAL MANUFACTURING SERVICES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2022 57
4.3 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2023 VS. 2028 (USD BILLION) 58
FIGURE 17 PHARMACEUTICAL MANUFACTURING SERVICES SEGMENT TO DOMINATE MARKET TILL 2028 58
4.4 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SHARE, BY END USER, 2022 58
FIGURE 18 BIG PHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 58
4.5 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
FIGURE 19 ASIA PACIFIC TO REGISTER HIGHEST GROWTH FROM 2023 TO 2028 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
FIGURE 20 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
TABLE 4 PHARMACEUTICAL CONTRACT MANUFACTURING AND DEVELOPMENT MARKET: IMPACT ANALYSIS 61
5.2.1 DRIVERS 61
5.2.1.1 Increased investment in precision medicines 61

5.2.1.2 Patent expiry & increasing demand for generic drugs 62
TABLE 5 IMPENDING PATENT EXPIRY OF BLOCKBUSTER DRUGS, BY YEAR 62
5.2.1.3 High cost of in-house drug development 62
FIGURE 21 AVERAGE COST OF DEVELOPING PHARMACEUTICAL COMPOUNDS FROM DISCOVERY TO LAUNCH, 2010–2020 (USD BILLION) 63
5.2.1.4 Investments in advanced manufacturing technologies by CDMOs 63
5.2.2 RESTRAINTS 64
5.2.2.1 Varying regulatory requirements across regions 64
5.2.3 OPPORTUNITIES 64
5.2.3.1 Rising demand for cell & gene therapy 64
TABLE 6 EXPANSIONS BY TOP COMPANIES IN 2022 64
5.2.3.2 Growing inclination toward one-stop-shop model 65
5.2.3.3 Market expansion in emerging countries 65
5.2.3.4 Growth of nuclear medicine 66
5.2.4 CHALLENGES 66
5.2.4.1 Introduction of serialization 66
5.2.4.2 Intellectual property risk 67
5.3 VALUE CHAIN ANALYSIS 67
FIGURE 22 VALUE CHAIN ANALYSIS: API PRODUCTION AND FORMULATION ADD MAXIMUM VALUE 68
5.4 ECOSYSTEM ANALYSIS 68
FIGURE 23 ECOSYSTEM ANALYSIS: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 68
TABLE 7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: ROLE IN ECOSYSTEM 69
5.5 TECHNOLOGY ANALYSIS 70
5.6 PORTER’S FIVE FORCES ANALYSIS 71
TABLE 8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS 71
5.6.1 THREAT OF NEW ENTRANTS 71
5.6.2 THREAT OF SUBSTITUTES 71
5.6.3 BARGAINING POWER OF SUPPLIERS 71
5.6.4 BARGAINING POWER OF BUYERS 72
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 72
5.7 REGULATORY ANALYSIS 72
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
TABLE 12 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74
TABLE 13 REGULATORY SCENARIO IN DIFFERENT COUNTRIES 74

5.8 KEY CONFERENCES & EVENTS, 2022–2023 77
TABLE 14 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2022–2023 77
5.9 KEY STAKEHOLDERS AND BUYING CRITERIA 78
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS 78
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CDMO SERVICES 78
5.9.2 BUYING CRITERIA 78
FIGURE 25 KEY BUYING CRITERIA FOR END USERS 78
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESS 79
FIGURE 26 REVENUE SHIFT & NEW POCKETS FOR PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 79
5.11 ANDA APPROVALS 79
FIGURE 27 ANDA APPROVALS, 2018–2022 79
FIGURE 28 REGIONAL BREAKDOWN OF ANDA APPROVALS IN 2022 80
FIGURE 29 ANDA APPROVALS IN 2022, BY DOSAGE FORM 80
6 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE 81
6.1 INTRODUCTION 82
TABLE 15 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 82
6.2 PHARMACEUTICAL MANUFACTURING SERVICES 82
TABLE 16 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 83
TABLE 17 PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 83
TABLE 18 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 83
TABLE 19 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 84
TABLE 20 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 84
TABLE 21 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 85
6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES 85
6.2.1.1 Need to focus on core areas to drive pharma companies to outsource API manufacturing 85
TABLE 22 PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 86
TABLE 23 NORTH AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 86
TABLE 24 EUROPE: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 87
TABLE 25 ASIA PACIFIC: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 87
TABLE 26 LATIN AMERICA: PHARMACEUTICAL API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 88
6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES 88
TABLE 27 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 89
TABLE 28 PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 89
TABLE 29 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 90
TABLE 30 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 90
TABLE 31 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 91
TABLE 32 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 91
6.2.2.1 Parenteral/Injectable manufacturing services 91
6.2.2.1.1 Increasing investments in drug development to support market growth 91
TABLE 33 PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 92
TABLE 34 NORTH AMERICA: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 92
TABLE 35 EUROPE: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 93
TABLE 36 ASIA PACIFIC: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 93
TABLE 37 LATIN AMERICA: PARENTERAL/INJECTABLE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 94
6.2.2.2 Tablet manufacturing services 94
6.2.2.2.1 Growing production capacity for tablet manufacturing in emerging markets to support growth 94
TABLE 38 TABLET MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 94
TABLE 39 NORTH AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 95
TABLE 40 EUROPE: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 95
TABLE 41 ASIA PACIFIC: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 96
TABLE 42 LATIN AMERICA: TABLET MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 96
6.2.2.3 Capsule manufacturing services 96
6.2.2.3.1 Popularity of capsules to ensure demand for contract manufacturing 96
TABLE 43 CAPSULE MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 97
TABLE 44 NORTH AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 97
TABLE 45 EUROPE: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 98
TABLE 46 ASIA PACIFIC: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 98
TABLE 47 LATIN AMERICA: CAPSULE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 99
6.2.2.4 Oral liquid manufacturing services 99
6.2.2.4.1 Complexities in handling liquids to promote outsourcing 99
TABLE 48 ORAL LIQUID MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 100
TABLE 49 NORTH AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 100
TABLE 50 EUROPE: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 101
TABLE 51 ASIA PACIFIC: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 101
TABLE 52 LATIN AMERICA: ORAL LIQUID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 102
6.2.2.5 Semi-solid manufacturing services 102
6.2.2.5.1 Need for specialized facilities to boost outsourcing of semi-solid manufacturing 102
TABLE 53 SEMI-SOLID MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 103
TABLE 54 NORTH AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 103
TABLE 55 EUROPE: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 104
TABLE 56 ASIA PACIFIC: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 104
TABLE 57 LATIN AMERICA: SEMI-SOLID MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 105
6.2.2.6 Other FDF manufacturing services 105
TABLE 58 OTHER FDF MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 106
TABLE 59 NORTH AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 106
TABLE 60 EUROPE: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 107
TABLE 61 ASIA PACIFIC: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 107
TABLE 62 LATIN AMERICA: OTHER FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 108
6.3 DRUG DEVELOPMENT SERVICES 108
6.3.1 HIGH COST OF DEVELOPMENT TO BOOST OUTSOURCING 108
TABLE 63 DRUG DEVELOPMENT SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 109
TABLE 64 NORTH AMERICA: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 109
TABLE 65 EUROPE: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 110
TABLE 66 ASIA PACIFIC: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 110
TABLE 67 LATIN AMERICA: DRUG DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 111
6.4 BIOLOGIC MANUFACTURING SERVICES 111
TABLE 68 BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 112
TABLE 69 BIOLOGIC MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 112
TABLE 70 NORTH AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 112
TABLE 71 EUROPE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 113
TABLE 72 ASIA PACIFIC: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 113
TABLE 73 LATIN AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 114
6.4.1 BIOLOGIC API MANUFACTURING SERVICES 114
6.4.1.1 Rising interest in biologics to ensure growth of nascent contract manufacturing sector 114
TABLE 74 BIOLOGIC API MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 115
TABLE 75 NORTH AMERICA: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 115
TABLE 76 EUROPE: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 116
TABLE 77 ASIA PACIFIC: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 116
TABLE 78 LATIN AMERICA: BIOLOGIC API MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 117
6.4.2 BIOLOGIC FDF MANUFACTURING SERVICES 117
6.4.2.1 Growing R&D costs and process complexity to favor contract manufacturing 117
TABLE 79 BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD BILLION) 117
TABLE 80 NORTH AMERICA: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 118
TABLE 81 EUROPE: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 118
TABLE 82 ASIA PACIFIC: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 119
TABLE 83 LATIN AMERICA: BIOLOGIC FDF MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 119

7 PHARMACEUTICAL CONTRACT DEVELOPMENT AND
MANUFACTURING MARKET, BY END USER 120
7.1 INTRODUCTION 121
TABLE 84 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 121
7.2 BIG PHARMACEUTICAL COMPANIES 121
7.2.1 EMERGENCE OF NEW MEDICINES AND THERAPIES TO CONTRIBUTE TO MARKET GROWTH 121
TABLE 85 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 122
TABLE 86 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 123
TABLE 87 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 123
TABLE 88 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 124
TABLE 89 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR BIG PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 124
7.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES 124
7.3.1 GROWING DEVELOPMENT OF BIOLOGICS AND HIGH PRICING PRESSURE TO BOOST MARKET 124
TABLE 90 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD BILLION) 125
TABLE 91 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 126
TABLE 92 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 126
TABLE 93 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 127
TABLE 94 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 127
7.4 GENERIC PHARMACEUTICAL COMPANIES 127
7.4.1 RISING DEMAND FOR GENERICS TO PROPEL MARKET 127
TABLE 95 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD BILLION) 128
TABLE 96 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 128
TABLE 97 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 129
TABLE 98 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 129
TABLE 99 LATIN AMERICA PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR GENERIC PHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD BILLION) 130
7.5 OTHER END USERS 130
TABLE 100 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD BILLION) 130
TABLE 101 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD BILLION) 131
TABLE 102 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD BILLION) 131
TABLE 103 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD BILLION) 132
TABLE 104 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD BILLION) 132
8 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION 133
8.1 INTRODUCTION 134
TABLE 105 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY REGION, 2021–2028 (USD BILLION) 134
8.2 NORTH AMERICA 134
FIGURE 30 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT 135
TABLE 106 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 136
TABLE 107 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 136
TABLE 108 NORTH AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 136
TABLE 109 NORTH AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 137
TABLE 110 NORTH AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 137
TABLE 111 NORTH AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 138
8.2.1 US 138
8.2.1.1 US to dominate North American market 138
TABLE 112 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 139
TABLE 113 US: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 139
TABLE 114 US: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 140
TABLE 115 US: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 140
TABLE 116 US: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 141
8.2.2 CANADA 141
8.2.2.1 Rising government funding and support to propel market 141
TABLE 117 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 142
TABLE 118 CANADA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 142
TABLE 119 CANADA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 143
TABLE 120 CANADA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 143
TABLE 121 CANADA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 144
8.2.3 NORTH AMERICA: RECESSION IMPACT 144
8.3 EUROPE 145
TABLE 122 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 145
TABLE 123 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 146
TABLE 124 EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 146
TABLE 125 EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 147
TABLE 126 EUROPE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 147
TABLE 127 EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 148
8.3.1 GERMANY 148
8.3.1.1 Germany to hold largest share throughout forecast period 148
TABLE 128 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 149
TABLE 129 GERMANY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 149
TABLE 130 GERMANY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 150
TABLE 131 GERMANY: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 150
TABLE 132 GERMANY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 151
8.3.2 UK 151
8.3.2.1 Rising investments in drug development to favor market growth 151
TABLE 133 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 152
TABLE 134 UK: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 152
TABLE 135 UK: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 153
TABLE 136 UK: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 153
TABLE 137 UK: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 154
8.3.3 FRANCE 154
8.3.3.1 Growing generics segment, favorable government policies, and growing clinical trials to drive market 154
TABLE 138 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 155
TABLE 139 FRANCE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 155
TABLE 140 FRANCE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 156
TABLE 141 FRANCE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 156
TABLE 142 FRANCE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 157
8.3.4 ITALY 157
8.3.4.1 Rising commercial drug development pipeline in Europe to favor market growth 157
TABLE 143 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 158
TABLE 144 ITALY: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 158
TABLE 145 ITALY: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 159
TABLE 146 ITALY: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 159
TABLE 147 ITALY: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 160
8.3.5 SWITZERLAND 160
8.3.5.1 Growing pharmaceutical industry to support growth 160
TABLE 148 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 161
TABLE 149 SWITZERLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 161
TABLE 150 SWITZERLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 162
TABLE 151 SWITZERLAND: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 162
TABLE 152 SWITZERLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 163

8.3.6 POLAND 163
8.3.6.1 Increasing support for life science R&D to propel market 163
TABLE 153 POLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 164
TABLE 154 POLAND: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 164
TABLE 155 POLAND: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 165
TABLE 156 POLAND: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 165
TABLE 157 POLAND: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 166
8.3.7 SPAIN 166
8.3.7.1 Rising R&D expenditure to boost market 166
TABLE 158 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 167
TABLE 159 SPAIN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 167
TABLE 160 SPAIN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 168
TABLE 161 SPAIN: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 168
TABLE 162 SPAIN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 169
8.3.8 REST OF EUROPE 169
TABLE 163 REST OF EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 170
TABLE 164 REST OF EUROPE: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 170
TABLE 165 REST OF EUROPE: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 171
TABLE 166 REST OF EUROPE: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 171
TABLE 167 REST OF EUROPE: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 172
8.3.9 EUROPE: RECESSION IMPACT 172
8.4 ASIA PACIFIC 173
FIGURE 31 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SNAPSHOT 174
TABLE 168 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 175
TABLE 169 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 175
TABLE 170 ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 175
TABLE 171 ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 176
TABLE 172 ASIA PACIFIC: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 176
TABLE 173 ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 177
8.4.1 CHINA 177
8.4.1.1 China to hold largest share of Asia Pacific market 177
TABLE 174 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 178
TABLE 175 CHINA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 178
TABLE 176 CHINA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 179
TABLE 177 CHINA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 179
TABLE 178 CHINA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 180
8.4.2 INDIA 180
8.4.2.1 Increasing pharma R&D activities and government funding for biotechnology to support market growth 180
TABLE 179 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 181
TABLE 180 INDIA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 181
TABLE 181 INDIA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 182
TABLE 182 INDIA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 182
TABLE 183 INDIA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 183
8.4.3 JAPAN 183
8.4.3.1 Growing generics demand and government initiatives to drive demand for contract manufacturing 183
TABLE 184 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 184
TABLE 185 JAPAN: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 184
TABLE 186 JAPAN: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 185
TABLE 187 JAPAN: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 185
TABLE 188 JAPAN: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 186
8.4.4 SOUTH KOREA 186
8.4.4.1 Government initiatives and growing R&D activities for drug development to drive market growth 186
TABLE 189 SOUTH KOREA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 187
TABLE 190 SOUTH KOREA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 187
TABLE 191 SOUTH KOREA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 188
TABLE 192 SOUTH KOREA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 188
TABLE 193 SOUTH KOREA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 189
8.4.5 REST OF ASIA PACIFIC 189
TABLE 194 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 190
TABLE 195 REST OF ASIA PACIFIC: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 190
TABLE 196 REST OF ASIA PACIFIC: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 191
TABLE 197 REST OF ASIA PACIFIC: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 191
TABLE 198 REST OF ASIA PACIFIC: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 192
8.4.6 ASIA PACIFIC: RECESSION IMPACT 192
8.5 LATIN AMERICA 193
TABLE 199 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD BILLION) 193
TABLE 200 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 193
TABLE 201 LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 194
TABLE 202 LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 194
TABLE 203 LATIN AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 194
TABLE 204 LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 195
8.5.1 BRAZIL 195
8.5.1.1 Growing pharmaceutical industry to drive market 195
TABLE 205 BRAZIL: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 196
TABLE 206 BRAZIL: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 196
TABLE 207 BRAZIL: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 196
TABLE 208 BRAZIL: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 197
TABLE 209 BRAZIL: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 197

8.5.2 REST OF LATIN AMERICA 197
TABLE 210 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 198
TABLE 211 REST OF LATIN AMERICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 198
TABLE 212 REST OF LATIN AMERICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 199
TABLE 213 REST OF LATIN AMERICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 199
TABLE 214 REST OF LATIN AMERICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 200
8.5.3 LATIN AMERICA: RECESSION IMPACT 200
8.6 MIDDLE EAST & AFRICA 201
8.6.1 UAE AND SAUDI ARABIA TO SHOW SIGNIFICANT GROWTH 201
TABLE 215 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY SERVICE, 2021–2028 (USD BILLION) 201
TABLE 216 MIDDLE EAST & AFRICA: PHARMACEUTICAL MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 202
TABLE 217 MIDDLE EAST & AFRICA: PHARMACEUTICAL FDF MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 202
TABLE 218 MIDDLE EAST & AFRICA: BIOLOGIC MANUFACTURING SERVICES MARKET, BY TYPE, 2021–2028 (USD BILLION) 203
TABLE 219 MIDDLE EAST & AFRICA: PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, BY END USER, 2021–2028 (USD BILLION) 203
8.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 203
9 COMPETITIVE LANDSCAPE 204
9.1 OVERVIEW 204
9.2 KEY PLAYER STRATEGIES 204
TABLE 220 KEY STRATEGIES ADOPTED BY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET, 2020–2023 204
9.3 REVENUE SHARE ANALYSIS 206
FIGURE 32 REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2020–2022 206
9.4 MARKET SHARE ANALYSIS 207
FIGURE 33 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET SHARE ANALYSIS, BY KEY PLAYER, 2022 207
TABLE 221 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEGREE OF COMPETITION 207
9.5 COMPANY EVALUATION QUADRANT FOR KEY PLAYERS, 2022 208
9.5.1 STARS 208
9.5.2 EMERGING LEADERS 208
9.5.3 PERVASIVE PLAYERS 209
9.5.4 PARTICIPANTS 209
FIGURE 34 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPANY EVALUATION QUADRANT, 2022 209
9.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 210
9.6.1 SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES) 210
TABLE 222 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 210
 
9.6.2 END-USER FOOTPRINT OF COMPANIES (25 COMPANIES) 211
TABLE 223 END-USER FOOTPRINT ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 211
9.6.3 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES) 213
TABLE 224 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET 213
9.7 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES (2022) 214
9.7.1 PROGRESSIVE COMPANIES 214
9.7.2 STARTING BLOCKS 214
9.7.3 RESPONSIVE COMPANIES 214
9.7.4 DYNAMIC COMPANIES 214
FIGURE 35 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2022 215
9.8 COMPETITIVE BENCHMARKING OF START-UPS/SMES 215
TABLE 225 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS 215
TABLE 226 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 216
9.9 COMPETITIVE SCENARIO AND TRENDS 217
9.9.1 SERVICE LAUNCHES 217
TABLE 227 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: SERVICE LAUNCHES, JANUARY 2020–MARCH 2023 217
9.9.2 DEALS 217
TABLE 228 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: DEALS, JANUARY 2020–MARCH 2023 217
9.9.3 OTHER DEVELOPMENTS 218
TABLE 229 PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING MARKET: OTHER DEVELOPMENTS, JANUARY 2020–MARCH 2023 218
10 COMPANY PROFILES 219
10.1 KEY MARKET PLAYERS 219
(Business Overview, Services Offered, Recent Developments, and MnM View)*
10.1.1 THERMO FISHER SCIENTIFIC, INC. 219
TABLE 230 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 219
FIGURE 36 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 220
10.1.2 CATALENT, INC. 223
TABLE 231 CATALENT, INC.: BUSINESS OVERVIEW 223
FIGURE 37 CATALENT, INC.: COMPANY SNAPSHOT (2022) 224
10.1.3 LONZA GROUP 231
TABLE 232 LONZA GROUP: BUSINESS OVERVIEW 231
FIGURE 38 LONZA GROUP: COMPANY SNAPSHOT (2022) 232
10.1.4 ABBVIE, INC. 237
TABLE 233 ABBVIE, INC.: BUSINESS OVERVIEW 237
FIGURE 39 ABBVIE, INC.: COMPANY SNAPSHOT (2022) 238
10.1.5 WUXI APPTEC 240
TABLE 234 WUXI APPTEC: BUSINESS OVERVIEW 240
FIGURE 40 WUXI APPTEC: COMPANY SNAPSHOT (2022) 241
10.1.6 EVONIK INDUSTRIES AG 243
TABLE 235 EVONIK INDUSTRIES AG: BUSINESS OVERVIEW 243
FIGURE 41 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2022) 244
10.1.7 SAMSUNG BIOLOGICS 246
TABLE 236 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW 246
FIGURE 42 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2022) 246
10.1.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 249
TABLE 237 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW 249
FIGURE 43 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022) 250
10.1.9 SIEGFRIED HOLDING AG 252
TABLE 238 SIEGFRIED HOLDING AG: BUSINESS OVERVIEW 252
FIGURE 44 SIEGFRIED HOLDING AG: COMPANY SNAPSHOT (2022) 252
10.1.10 FUJIFILM HOLDINGS CORPORATION 254
TABLE 239 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW 254
FIGURE 45 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022) 255
10.1.11 EUROFINS SCIENTIFIC 258
TABLE 240 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 258
FIGURE 46 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022) 258
10.1.12 PIRAMAL PHARMA SOLUTIONS 261
TABLE 241 PIRAMAL PHARMA SOLUTIONS: BUSINESS OVERVIEW 261
FIGURE 47 PIRAMAL PHARMA SOLUTIONS: COMPANY SNAPSHOT (2022) 262
10.1.13 RECIPHARM AB 265
TABLE 242 RECIPHARM AB: BUSINESS OVERVIEW 265
10.1.14 ALMAC GROUP 268
TABLE 243 ALMAC GROUP: BUSINESS OVERVIEW 268
10.1.15 VETTER PHARMA 270
TABLE 244 VETTER PHARMA: BUSINESS OVERVIEW 270
* Business Overview, Services Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
10.2 OTHER PLAYERS 272
10.2.1 DELPHARM HOLDINGS 272
10.2.2 YUHAN CORPORATION 273
10.2.3 CURIA GLOBAL, INC. 274
10.2.4 CHARLES RIVER LABORATORIES 275
10.2.5 LANNETT COMPANY, INC. 276
10.2.6 CAMBREX CORPORATION 277
10.2.7 FAMAR HEALTHCARE SERVICES 278
10.2.8 SYNGENE INTERNATIONAL LIMITED (BIOCON LIMITED) 279
10.2.9 SAI LIFE SCIENCES LIMITED 280
10.2.10 PCI PHARMA SERVICES 281
11 APPENDIX 282
11.1 DISCUSSION GUIDE 282
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 286
11.3 CUSTOMIZATION OPTIONS 288
11.4 RELATED REPORTS 288
11.5 AUTHOR DETAILS 289

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • バイオテクノロジー受託製造のグローバル市場予測（～2028）：製造、充填仕上げ、包装
  • 臨床試験用品の世界市場予測（～2028）：サービス別、フェーズ別、種類別、治療領域別、エンドユーザー別、地域別
  • 患者腫瘍移植/PDXモデルのグローバル市場予測（～2028）：マウス、ラット
  • カスタム抗体の世界市場予測（～2028）：サービス別、種類別、ソース別、用途別、疾患別、エンドユーザー別
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(PH7263-23 )"医薬品受託製造のグローバル市場予測（～2028）：医薬品製造サービス、医薬品開発サービス、生物製剤製造サービス" (英文：Pharmaceutical Contract Manufacturing Market by Service (Pharmaceutical (API, FDF - Tablet, Capsule, Injectable)), Biologic (API, FDF), Drug Development), End User (Big Pharma, Small & Medium-sized Pharma, Generic Pharma) - Global Forecast to 2028)はMarketsandMarkets社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。